S&P Futures
3,317.75+17.75(+0.54%)Dow Futures
26,903.00+186.00(+0.70%)Nasdaq Futures
11,121.00+35.00(+0.32%)
Cara Therapeutics, Inc. (CARA)
Chart Events
Performance Outlook
| Previous Close | 17.15 |
| Open | 17.05 |
| Bid | 16.55 x 1200 |
| Ask | 0.00 x 1300 |
| Day's Range | 16.93 - 17.42 |
| 52 Week Range | 8.88 - 26.67 |
| Volume | 225,717 |
| Avg. Volume | 494,512 |
| Market Cap | 806.297M |
| Beta (5Y Monthly) | 1.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.55 |
| Earnings Date | May 11, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.13 |
Fair Value
Related Research
- GlobeNewswire
Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
STAMFORD, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020, at 4:30 p.m. ET to report second quarter 2020 financial results and provide a corporate update. To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 7669087. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.About Cara TherapeuticsCara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Cara has successfully completed its Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with CKD and is currently conducting Phase 2 trials of Oral KORSUVA in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 astarr@6degreespr.comINVESTOR CONTACT: Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200 Janhavi.Mohite@sternir.com
- Investopedia
Top Marijuana Stocks on the NASDAQ for August 2020
These are the marijuana stocks on the nasdaq stocks with the best value, fastest growth, and best performance for August.
- Zacks
Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
